NO20024673L - Farmasöytisk sammensetning med kontrollert frigivning for oral anvendelse inneholdende midodrin og/eller desglymidodrin - Google Patents

Farmasöytisk sammensetning med kontrollert frigivning for oral anvendelse inneholdende midodrin og/eller desglymidodrin

Info

Publication number
NO20024673L
NO20024673L NO20024673A NO20024673A NO20024673L NO 20024673 L NO20024673 L NO 20024673L NO 20024673 A NO20024673 A NO 20024673A NO 20024673 A NO20024673 A NO 20024673A NO 20024673 L NO20024673 L NO 20024673L
Authority
NO
Norway
Prior art keywords
desglymidodrine
midodrine
oral use
release pharmaceutical
use containing
Prior art date
Application number
NO20024673A
Other languages
English (en)
Other versions
NO20024673D0 (no
Inventor
Annette Skinhoej
Peder Mohr Olsen
Poul Bertelsen
Original Assignee
Nycomed Austria Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Austria Gmbh filed Critical Nycomed Austria Gmbh
Publication of NO20024673D0 publication Critical patent/NO20024673D0/no
Publication of NO20024673L publication Critical patent/NO20024673L/no

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nanotechnology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20024673A 2000-03-31 2002-09-30 Farmasöytisk sammensetning med kontrollert frigivning for oral anvendelse inneholdende midodrin og/eller desglymidodrin NO20024673L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200000549 2000-03-31
US20378300P 2000-05-12 2000-05-12
PCT/DK2001/000213 WO2001074334A1 (en) 2000-03-31 2001-03-29 Controlled release pharmaceutical composition containing midodrine and/or desglymidodrine

Publications (2)

Publication Number Publication Date
NO20024673D0 NO20024673D0 (no) 2002-09-30
NO20024673L true NO20024673L (no) 2002-11-27

Family

ID=26068806

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20024673A NO20024673L (no) 2000-03-31 2002-09-30 Farmasöytisk sammensetning med kontrollert frigivning for oral anvendelse inneholdende midodrin og/eller desglymidodrin

Country Status (10)

Country Link
EP (1) EP1267841B1 (no)
JP (1) JP2003528909A (no)
CN (1) CN1422150A (no)
AT (1) ATE283036T1 (no)
AU (1) AU2001246388A1 (no)
CA (1) CA2403886A1 (no)
DE (1) DE60107399D1 (no)
EE (1) EE200200556A (no)
NO (1) NO20024673L (no)
WO (1) WO2001074334A1 (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001089473A1 (en) * 2000-05-26 2001-11-29 Nycomed Austria Gmbh Pharmaceutical compositions comprising desglymidodrine as an active drug substance
CA2936748C (en) 2014-10-31 2017-08-08 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
EP3518910A4 (en) * 2016-09-30 2020-11-04 Xenamed Corporation MIDODRIN COMPOSITIONS AND METHOD OF USE THEREOF
AU2017346267A1 (en) * 2016-10-21 2019-05-16 Cellvertics Co., Ltd. Pharmaceutical composition for preventing or treating diabetes and/or hyperlipidemia comprising midorine or pharmaceutically acceptable salt thereof as active ingredient
US11013702B2 (en) 2017-10-10 2021-05-25 Vertice Pharma, Llc Midodrine hydrochloride oral solution and uses thereof
US20200338025A1 (en) * 2017-12-22 2020-10-29 Xenamed Corp. Extended release midodrine hydrochloride compositions and methods of use
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
KR102151051B1 (ko) * 2019-01-10 2020-09-02 고려대학교 산학협력단 당뇨병성 백내장 치료 또는 예방용 조성물
WO2022157633A1 (en) * 2021-01-20 2022-07-28 Cadila Healthcare Limited Enantiomerically pure desglymidodrine and process for preparation thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3417576A1 (de) * 1984-05-11 1985-11-14 Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München Retardformen des alpha-(2,5-dimethoxy-phenyl)-ss-glycinamidoaethanols und verfahren zu ihrer herstellung
AT383270B (de) * 1984-05-15 1987-06-10 Chemie Linz Ag Verfahren zur herstellung von oralen retardformen des alpha-(2,5-dimethoxy-phenyl)-betaglycinamido|thanols
EP0423484B1 (de) * 1989-10-16 1993-11-03 PCD-Polymere Gesellschaft m.b.H. Pressling mit retardierter Wirkstofffreisetzung

Also Published As

Publication number Publication date
DE60107399D1 (de) 2004-12-30
CA2403886A1 (en) 2001-10-11
CN1422150A (zh) 2003-06-04
AU2001246388A1 (en) 2001-10-15
NO20024673D0 (no) 2002-09-30
ATE283036T1 (de) 2004-12-15
EP1267841A1 (en) 2003-01-02
EP1267841B1 (en) 2004-11-24
JP2003528909A (ja) 2003-09-30
EE200200556A (et) 2004-04-15
WO2001074334A1 (en) 2001-10-11

Similar Documents

Publication Publication Date Title
EA200800161A1 (ru) Новые фармацевтические композиции с модифицированным высвобождением и способ получения таких композиций
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
EA200201044A1 (ru) Фармацевтическая композиция с контролируемым высвобождением, содержащая мидодрин и/или десглимидодрин
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
BR0205722A (pt) Formulação de liberação prolongada e método para o tratamento de um paciente que sofre de dor
RU2006109467A (ru) Способы лечения рака с использованием ингибиторов hdac
ES2295609T3 (es) Derivados de tiadiazolilpiperazina utiles para tratar o prevenir un dolor.
EP2248519A3 (en) Non-mucoadhesive film dosage forms
IS6557A (is) Blandaðar sjúkdómsmeðferðir úr blóðþrýstingslækkandi efnum og efnum sem hamla æðamyndun
YU71901A (sh) NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I beta-MIMETIKA
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
HUP0400313A2 (hu) Új, biotechnológiai úton előállított, humán terápiára alkalmas szuperantigének
DK1256339T3 (da) Transdermalt terapeutisk system for opnåelse af høje plasmaniveauer af rotigotin i behandlingen af Parkinsons sygdom
UA90893C2 (ru) Пероральная дозированная форма производных гемцитабина
CO5640120A2 (es) Formulacion y metodods para el tratamiento de trombocitemia
EA200700777A1 (ru) Содержащие октенидин таблетки для рассасывания, предназначенные для лечения воспалительных заболеваний полости рта и глотки
NO20045240L (no) Transepikutan administrasjonsform for a behandle restless legs syndromet
RU2008110740A (ru) Твердые фармацевтические композиции, включающие 1-(4-хлоранилино)-4-(4-пиридилметил)фталазин и модификатор рн
WO2007064448A3 (en) Cancer treatment using fts and 2-deoxyglucose
ATE369355T1 (de) Pyrimidinamid derivate und deren verwendung
ATE298324T1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
NO20024673D0 (no) Farmasöytisk sammensetning med kontrollert frigivning for oral anvendelse inneholdende midodrin og/eller desglymidodrin
BR0311903A (pt) Tratamento para depressão e ansiedade pela combinação de um inibidor de pde iv e um agente antidepressivo ou ansiolìtico
EP1262197A3 (en) Combination treatment for sleep disorders including sleep apnea
EA200700979A1 (ru) Пероральные твердые лекарственные формы, содержащие низкую дозу эстрадиола

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application